Mark Alles. Celgene

Mark Alles be­gins his post-Cel­gene ca­reer on the board of a US-Chi­na biotech led by a for­mer col­league

An­ten­gene had Cel­gene writ­ten all over its brand. Its founder and CEO, Jay Mei, was the big biotech’s ex­ec­u­tive di­rec­tor of clin­i­cal de­vel­op­ment in hema­tol­ogy/on­col­o­gy for eight years be­fore launch­ing his own start­up in Chi­na with his for­mer em­ploy­er as a part­ner and in­vestor. Cel­gene chipped in­to An­ten­gene’s $120 mil­lion round last year, and just days ago, it al­so wooed Cel­gene’s Chi­na gen­er­al man­ag­er to be its chief busi­ness of­fi­cer.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.